

## CLAIMS

What is claimed is:

1. A method for treating a human patient having a cutaneous metastatic cancer comprising:  
(a) administering topically an arsenic-containing pharmaceutical composition to a site of said cutaneous metastatic cancer of human patient, said arsenic-containing pharmaceutical composition including a therapeutically effective amount of an arsenic-containing compound and a pharmaceutically acceptable carrier; and (b) applying transcutaneously an electron beam to the site.
2. The method according to claim 1, further comprising the step of removing said arsenic-containing pharmaceutical composition from the site prior to step (b).
3. The method according to claim 1 wherein said cutaneous metastatic cancer is selected from the group consisting of breast cancer, colon cancer, ovary cancer, lung cancer, head and neck squamous cancer, and oral cavity cancer.
4. The method according to claim 1, wherein said cutaneous metastatic cancer is cutaneous metastatic breast cancer.
5. The method according to claim 1, wherein said arsenic-containing compound is selected from the group consisting of  $\text{As}_2\text{O}_3$ ,  $\text{As}_2\text{S}_3$ ,  $\text{As}_2\text{S}_2$  and a combination thereof.
6. The method according to claim 5, wherein the arsenic-containing compound is  $\text{As}_2\text{O}_3$ .
7. The method according to claim 1, wherein said arsenic-containing pharmaceutical composition is an arsenic-containing gel formulation.
8. The method according to claim 7, wherein said arsenic-containing pharmaceutical composition is administered in a daily dose ranging from 0.01 to 0.5 mg/cm<sup>2</sup>.
9. The method according to claim 8, wherein said daily dose ranges from 0.05 to 0.15 mg/cm<sup>2</sup>.
10. The method according to claim 1, wherein said electron beam is applied in a total radiation dose ranging from 30 to 50 Gy/5 days.